| Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. | |
| | |
MedLine Citation:
|
PMID: 19931080 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the effects of a pill with drospirenone (3 mg) plus ethinyl E(2) (20 μg) (DRP/20EE) alone or associated with metformin or cyproterone acetate (CPA) on some metabolic cardiovascular risk factors in women with polycystic ovary syndrome (PCOS). DESIGN: Randomized, open-label clinical trial. SETTING: Academic medical clinic. PATIENT(S): Forty-eight hirsute women with PCOS. INTERVENTION(S): Patients were randomized to treatment with DRP/20EE or with DRP/20EE plus metformin (1,500 mg/d) or with DRP/20EE plus CPA (12.5 mg/d, 10 days per cycle) for 6 months. MAIN OUTCOME MEASURE(S): Blood pressure, lipid profile, and indexes of glucose tolerance and insulin sensitivity were assessed before and after 6 months of treatment. RESULT(S): Body mass index and blood pressure were not modified by any treatment. Treatment with DRP/EE20 did not change the lipid profile; DRP/EE20 plus metformin significantly increased high-density lipoprotein cholesterol concentrations; DRP/EE20 plus CPA significantly increased triglycerides and total cholesterol. The area under the curve for insulin was significantly decreased by DRP/EE20 and DRP/EE20 plus metformin, but it was significantly increased by DRP/EE20 plus CPA. Treatment with DRP/EE20 plus CPA significantly increased the homeostasis model assessment of insulin resistance index and significantly reduced the glucose to insulin ratio index. Treatment with DRP/EE20 significantly increased the glucose to insulin ratio index. CONCLUSION(S): Treatment with DRP/EE20 improved insulin sensitivity in hirsute women with PCOS, with no deterioration of lipid profile. This effect was not ameliorated by the addition of metformin. The positive metabolic effects of DRP are abolished by the concomitant use of CPA. |
| | |
Authors:
|
Franca Fruzzetti; Daria Perini; Veronica Lazzarini; Donatella Parrini; Marco Gambacciani; Andrea Riccardo Genazzani |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Fertility and sterility Volume: 94 ISSN: 1556-5653 ISO Abbreviation: Fertil. Steril. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-27 Completed Date: 2010-11-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372772 Medline TA: Fertil Steril Country: United States |
Other Details:
|
Languages: eng Pagination: 1793-8 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Obstetrics and Gynecology, Ospedale S. Chiara, University of Pisa, Pisa, Italy. ffruzzi@tin.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adolescent Adult Aldosterone Antagonists / administration & dosage, adverse effects*, therapeutic use Androgens / blood Androstenes / administration & dosage, adverse effects*, therapeutic use Blood Pressure / physiology Cardiovascular Diseases / blood, epidemiology*, physiopathology Cyproterone / administration & dosage, adverse effects*, therapeutic use Dose-Response Relationship, Drug Drug Therapy, Combination Estrogens / administration & dosage, adverse effects, therapeutic use Ethinyl Estradiol / administration & dosage, adverse effects*, therapeutic use Female Glucose / metabolism Humans Hypoglycemic Agents / administration & dosage, adverse effects, therapeutic use Insulin / blood Lipids / blood Metformin / administration & dosage, adverse effects*, therapeutic use Polycystic Ovary Syndrome / blood, complications, drug therapy* Risk Factors Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Androgens; 0/Androstenes; 0/Estrogens; 0/Hypoglycemic Agents; 0/Lipids; 11061-68-0/Insulin; 2098-66-0/Cyproterone; 50-99-7/Glucose; 57-63-6/Ethinyl Estradiol; 657-24-9/Metformin; 67392-87-4/drospirenone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Growth differentiation factor 9 concentration in the follicular fluid of infertile women with endome...
Next Document: Role of polymorphonuclear neutrophils in atherosclerosis: Current state and future perspectives.